HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Demmy, T. L. Articles by Curtis, J. J. Search for Related Content PubMed PubMed Citation Articles by Demmy, T. L. Articles by Curtis, J. J.

The Annals of Thoracic Surgery, Vol 57, 648-651, Copyright © 1994 by The Society of Thoracic Surgeons

ARTICLES

Lack of cardioplegia uniformity in clinical myocardial preservation

TL Demmy, SP Haggerty, TM Boley and JJ Curtis
Division of Cardiothoracic Surgery, University of Missouri, Columbia 65212.

Advances in myocardial preservation have led to improved patient survival after open heart operations. However, few studies have detailed the nature of national or regional patterns of cardioplegia use. To determine the regional pattern, all open heart surgery programs in Missouri were surveyed. During 1 year, it was found that cardioplegia was administered to 8,382 patients by 61 cardiothoracic surgeons at ten academic affiliated hospitals and 16 nonteaching hospitals. All cardioplegic solutions were hospital produced. Of 13 crystalloid solutions, 11 differed from one another and eight were intracellular formulations. Of 28 multidose blood-based cardioplegic solutions, there were 23 different mixtures. Most crystalloid (69%) and blood-based (89%) solutions differed substantially from commonly reported formulations. The incidences of the various additives to crystalloid solutions were as follows: bicarbonate, 92%; glucose, 69%; lidocaine, 54%; mannitol, 46%; magnesium, 31%; calcium, 23%; methylprednisolone, 15%; heparin, 8%; and acetate, 8%. Of the common blood-based cardioplegic solution additives, the following incidences were observed: glucose, 79%; bicarbonate, 43%; trishydroxyaminomethane, 36%; acetate, 29%; magnesium, 29%; procaine (or lidocaine), 25%; citrate-phosphate-dextrose, 18%; mannitol/albumin, 14%; nitroglycerin, 11%; glutamate/aspartate, 11%; calcium, 7%; insulin, 3%; and methylprednisolone, 3%. No calcium channel blocker or high-energy phosphate additives were reported. We conclude that many different cardioplegic admixtures that have not been tested experimentally are used routinely in clinical practice, presumably with acceptable results. Because the salutary effects of induced cardiac arrest and hypothermia may mask suboptimal solutions, further study of customized cardioplegia should be considered, particularly with regard to high- risk patients.

This article has been cited by other articles:

				R. Ascione, M. Caputo, W.J. Gomes, A.A. Lotto, A.J. Bryan, G.D. Angelini, and M.-S. Suleiman Myocardial injury in hypertrophic hearts of patients undergoing aortic valve surgery using cold or warm blood cardioplegia Eur. J. Cardiothorac. Surg., March 1, 2002; 21(3): 440 - 446. [Abstract] [Full Text] [PDF]

				T. L. Demmy, T. A. Turpin, and C. C. Wagner-Mann Laboratory confirmation of clinical heart allograft preservation variability Ann. Thorac. Surg., April 1, 2001; 71(4): 1312 - 1319. [Abstract] [Full Text] [PDF]

				T. L. Demmy, J. A. Magovern, R. L. Kao, and G. J. Magovern Sr Hemolysis Within Infusion Systems May Accelerate Adenosine Degradation Ann. Thorac. Surg., October 1, 1996; 62(4): 1242 - 1242. [Full Text]

				L. A. Robinson, G. D. Schwarz, D. B. Goddard, W. H. Fleming, and T. A. Galbraith Myocardial Protection for Acquired Heart Disease Surgery: Results of a National Survey Ann. Thorac. Surg., February 1, 1995; 59(2): 361 - 372. [Abstract] [Full Text]